Publications by authors named "David Spriggs"

Claim this Profile
H
Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.
Mengyao Xu, Syem K Barakzai, Raj Kumar, Irva Veillard, Eugene Kim, David R Spriggs

Signal Transduct Target Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Yusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, David R Spriggs

Br J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Songfa Zhang, Chuan Yan, David G Millar, Qiqi Yang, James M Heather, David R Spriggs

Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.
Linah Al-Alem, Jillian M Prendergast, Justin Clark, Bianca Zarrella, Dominique T Zarrella, David R Spriggs

J Ovarian Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for antibody recognition of the proximal MUC16 ectodomain.
Kwangkook Lee, Kay Perry, Mengyao Xu, Irva Veillard, Raj Kumar, David R Spriggs

J Ovarian Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, Carolyn Krasner, Neil Horowitz, David Spriggs

JAMA Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents.
Thapi D Rao, Mengyao Xu, Stephanie Eng, Guangli Yang, Robin Manson, David R Spriggs

Mol Cancer Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Songfa Zhang, Chuan Yan, David G Millar, Qiqi Yang, James M Heather, David R Spriggs

Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal Brachytherapy.
Andrea L Russo, Larissa J Lee, Jennifer Y Wo, Andrzej Niemierko, Diane Park, David R Spriggs

Am J Clin Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Oladapo O Yeku, Thapi Dharma Rao, Ian Laster, Artem Kononenko, Terence J Purdon, David Spriggs

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.
Chrisann Kyi, Ekaterina Doubrovina, Qin Zhou, Sara Kravetz, Alexia Iasonos, David Spriggs

J Immunother Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
Brandon Nemieboka, Sai Kiran Sharma, Thapi Dharma Rao, Kimberly J Edwards, Su Yan, David R Spriggs

Nucl Med Biol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing cervical cancer screening disparities through advances in artificial intelligence and nanotechnologies for cellular profiling.
Zhenzhong Yang, Jack Francisco, Alexandra S Reese, David R Spriggs, Hyungsoon Im

Biophys Rev (Melville)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.
Marina Stasenko, Evan Smith, Oladapo Yeku, Kay J Park, Ian Laster, Elizabeth Spriggs, David R Spriggs

Sci Rep· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.
Oladapo Yeku, Andrea L Russo, Hang Lee, David Spriggs

J Transl Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galectins and Ovarian Cancer.
Chisa Shimada, Rui Xu, Linah Al-Alem, Marina Stasenko, David R Spriggs

Cancers (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells.
Chiara Bellio, Celeste DiGloria, David R Spriggs, Rosemary Foster, Whitfield B Growdon

Cancers (Basel)· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
Robert C Bast, Ursula A Matulonis, Anil K Sood, Ahmed A Ahmed, Adaobi E Amobi, David R Spriggs

Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case 18-2019: A 24-Year-Old Woman with a Pelvic Mass.
David R Spriggs, Alexander Melamed, Weier Li, Nida Safdar

N Engl J Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Yanxia Zhao, Jinghong Cao, Alexander Melamed, Michael Worley, Allison Gockley, David R Spriggs

Proc Natl Acad Sci U S A· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.
Tara E Soumerai, Mark T A Donoghue, Chaitanya Bandlamudi, Preethi Srinivasan, Matthew T Chang, David R Spriggs

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of feeding decisions in hospitalised adults with severe oropharyngeal dysphagia.
Louise McHutchison, Anna Miles, David Spriggs, Sisira Jayathissa

Australas J Ageing· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in BRCA-Mutated Ovarian Cancer.
David R Spriggs, Dan L Longo

N Engl J Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
Katherine LaVigne, David M Hyman, Qin C Zhou, Alexia Iasonos, William P Tew, David R Spriggs

Int J Gynecol Cancer· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.
Tomoya Yokota, Johanna Bendell, Patricia LoRusso, Takahiro Tsushima, Ved Desai, David R Spriggs

Br J Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis